A survey of US dermatologists highlights inconsistent screening practices for comorbidities in patients with lichen planus.

Statistically significant improvements observed across clinical endpoints; final cohort results expected in Q2 2025 ...

PITTSBURGH, April 08, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology ...

Lipella Pharmaceuticals has concluded subject enrollment in its multicentre Phase IIa trial of liposomal tacrolimus oral rinse LP-310, which is aimed at treating oral lichen planus (OLP).

Oral Lichen Planus Symptom Severity Measure (OLPSSM): Decreased from 14.92 ± 2.10 at baseline to 9.87 ± 2.27 at week 1 (p=0.032), 4.88 ± 2.15 at week 4 (p=0.003) and 8.42 ± 3.98 at week 6 (p=0 ...

What really impresses me at this time of year, at any time of year, actually, are the lichens. These otherworldly beings, ...

"The completion of enrollment in our Phase 2a trial marks an important step in advancing a non-steroidal, locally delivered treatment for oral lichen planus, an underserved condition with no ...